Pneumocystis jiroveci pneumonia(PJP)is one of the more common and serious opportunistic infections in patients with human immunodeficiency virus(HIV).With the use of immunosuppressants and chemotherapy drugs,most PJP cases reported in China are non-HIV immunosuppressed patients.Compound sulfamethoxazole(SMZco)is the first-line drug for the treatment of PJP,and there are wide individual differences in its pharmacokinetics.Through citing a PJP case treated with SMZco under drug monitoring,a systematic review was conducted from the aspects of SMZco pharmacokinetics,dose-related adverse reactions,and optimal therapeutic dose research.It aims to demonstrate the importance of drug monitoring for sulfamethoxazole therapy,which ensures the drug reaches effective therapeutic concentrations and the occurrence of its'adverse reactions was reduced.
Pneumocystis jiroveci pneumoniaCompound sulfamethoxazoleTherapeutic drug monitoring
国家科技期刊平台
NSTL
万方数据
